Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma

BACKGROUND: Vandetanib, added to cisplatin and radiation (RT) overcomes chemo RT and EGFR inhibitor resistance in head and neck squamous cell carcinoma (HNSCC) lines and models. METHODS: Patients with previously untreated HNSCC received vandetanib daily for 14 days (starting dose 100 mg) then vandet...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Head Neck
Main Authors: Papadimitrakopoulou, VA, Frank, SJ, Cohen, EW, Hirsch, FR, Myers, JN, Heymach, JV, Lin, H, Tran, HT, Chen, CR, Jimeno, A, Nedzi, L, Vasselli, JR, Lowe, ES, Raben, D
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4414661/
https://ncbi.nlm.nih.gov/pubmed/25352401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.23922
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados